A delegation of professors from Hubei University visited Keyuan Pharmaceutical, marking a collaborative effort between the university and the company to explore new avenues for industrial cooperation.


Publish Time:

2026-02-27

From February 26 to 27, Professor Chen Shouwen from Hubei University and his delegation visited Kexuan Pharmaceutical for a visit and exchange. Li Hongfu, Chairman of Kexuan Pharmaceutical, along with his team, provided full-time accompaniment throughout the visit. The two sides held an in-depth discussion on topics including core product R&D processes, market strategies, and industry-university collaboration.

From February 26 to 27, Professor Chen Shouwen and his delegation from Hubei University visited Keyuan Pharmaceutical for a visit and exchange. Li Hongfu, Chairman of Keyuan Pharmaceutical, along with his team, accompanied the visitors throughout the visit. The two sides held an in-depth discussion on topics including core product R&D processes, market strategies, and industry-university collaboration.

During the inspection, Professor Chen Shouwen and his delegation visited various production and R&D facilities, including the company’s exhibition hall, the injectable drug workshop, and the active pharmaceutical ingredient (API) plant. They conducted on-site observations of the company’s intelligent production lines, quality control systems, and industrialization layout. The research team highly praised the company’s fully integrated, intelligent production system, large-scale manufacturing capabilities, sophisticated quality control standards, and continuous investment in R&D and innovation demonstrated in the fields of chemical APIs and finished dosage forms.

During the roundtable discussion, Chairman Li Hongfu warmly welcomed Professor Chen Shouwen and his delegation. He noted that Keyuan Pharmaceutical, as a publicly listed company deeply engaged in the R&D, production, and sales of chemical APIs, formulations, and pharmaceutical intermediates, has built solid core competencies in areas such as product process optimization, quality system development, and market channel deployment. The company has always remained focused on its core business, driven by R&D innovation, and continues to advance the optimization of its product portfolio in the field of biomanufacturing. This exchange with Professor Chen’s team represents an important step for the company to deepen university-enterprise cooperation and promote the integration of industry, academia, and research. We look forward to leveraging technology as a bridge to explore even more synergies and opportunities for industrial collaboration.

Drawing on his own research achievements in synthetic biology and microbial cell factories, Professor Chen Shouwen shared insights into the application prospects and technological breakthrough directions of biomanufacturing technologies in pharmaceutical raw material development and process optimization. He noted that Keyuan Pharmaceutical’s deep-rooted experience and well-rounded strategic layout in the pharmaceutical industrialization field provide an excellent platform for university-enterprise collaboration and technology commercialization. Both parties should leverage the research strengths of universities and the industrialization capabilities of enterprises, focus on upgrading core product processes and driving R&D innovation, accelerate the transformation of scientific and technological achievements, and achieve complementary advantages and mutual value creation.

This visit has injected new momentum into Kexuan Pharmaceutical’s efforts to deepen university-enterprise cooperation, advance technological R&D, and promote industrial upgrading. The company will continue to adopt an open attitude, strengthening exchanges and collaboration with universities, research institutions, and high-quality enterprises. Focusing on the development trends of the bio-manufacturing industry, we will delve deeper into R&D innovation and process optimization, accelerate the implementation and commercialization of more high-quality technological achievements, and contribute to the high-quality development of the pharmaceutical industry.